Gilead Sciences Inc
(GILD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,022,993 | 1,482,639 | 936,880 | 1,272,958 | 1,024,599 |
| Marketable Securities | 1,284,538 | 518,286 | 715,308 | 384,017 | 330,713 |
| Receivables | 1,670,405 | 1,482,900 | 1,491,332 | 1,389,534 | 1,339,165 |
| Inventories | 1,273,389 | 1,356,606 | 1,223,945 | 1,051,771 | 1,017,827 |
| Income taxes - deferred | 310,316 | 288,642 | 283,585 | 295,080 | 192,701 |
| Other current assets | 111,651 | 243,550 | 139,880 | 66,891 | 59,714 |
| TOTAL | $6,031,947 | $5,709,014 | $5,124,228 | $4,812,558 | $4,297,610 |
| Non-Current Assets | |||||
| PPE Net | 692,032 | 695,043 | 695,601 | 699,970 | 701,371 |
| Investments And Advances | 2,744,150 | 2,216,610 | 2,967,727 | 2,247,871 | 1,936,818 |
| Intangibles | 1,576,573 | 1,494,813 | 1,509,794 | 1,524,777 | 1,555,602 |
| Other Non-Current Assets | 410,889 | 381,228 | 398,648 | 413,383 | 445,579 |
| TOTAL | $5,423,644 | $4,787,694 | $5,571,770 | $4,886,001 | $4,639,370 |
| Total Assets | $11,455,590 | $10,496,710 | $10,696,000 | $9,698,559 | $8,936,980 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 1,124,230 | 7,088 | N/A | 205,613 |
| Accounts payable and accrued liabilities | 950,813 | 1,066,433 | 949,084 | 810,544 | 742,684 |
| Accrued Expenses | 428,642 | 400,613 | 381,847 | 381,141 | 356,398 |
| TOTAL | $2,590,108 | $3,105,723 | $1,887,651 | $1,871,631 | $1,889,249 |
| Non-Current Liabilities | |||||
| Long Term Debt | 47,760 | 23,050 | 27,290 | 35,918 | 42,363 |
| Deferred Revenues | 95,794 | 116,360 | 122,240 | 122,721 | 49,362 |
| Other Non-Current Liabilities | 2,902,218 | 631,343 | 1,239,703 | 1,245,645 | 1,211,199 |
| TOTAL | $2,986,711 | $690,985 | $1,305,675 | $1,321,770 | $1,295,574 |
| Total Liabilities | $5,576,819 | $3,796,708 | $3,193,326 | $3,193,401 | $3,184,823 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,623,735 | 1,677,265 | 1,779,830 | 1,806,758 | 1,799,850 |
| Common Shares | 815 | 860 | 902 | 900 | 902 |
| Retained earnings | 1,122,030 | 1,831,381 | 2,688,679 | 1,995,272 | 1,420,613 |
| Other shareholders' equity | 179,943 | 327,129 | 244,149 | 132,335 | 66,420 |
| TOTAL | $5,878,772 | $6,700,000 | $7,502,672 | $6,505,158 | $5,752,157 |
| Total Liabilities And Equity | $11,455,591 | $10,496,708 | $10,695,998 | $9,698,559 | $8,936,980 |